4 Stocks Dragging In The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 14 points (-0.1%) at 15,098 as of Friday, Aug. 16, 2013, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,393 issues advancing vs. 1,555 declining with 92 unchanged.

The Drugs industry currently is unchanged today versus the S&P 500, which is down 0.1%. A company within the industry that fell today was Eli Lilly and Company ( LLY), up 0.7%. A company within the industry that increased today was Biogen Idec ( BIIB), up 0.5%.

TheStreet would like to highlight 4 stocks pushing the industry lower today:

4. Novartis ( NVS) is one of the companies pushing the Drugs industry lower today. As of noon trading, Novartis is down $0.40 (-0.6%) to $72.94 on light volume. Thus far, 520,280 shares of Novartis exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $72.91-$73.43 after having opened the day at $73.34 as compared to the previous trading day's close of $73.34.

Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Novartis has a market cap of $180.1 billion and is part of the health care sector. Shares are up 15.9% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate Novartis a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Novartis Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Perrigo Company ( PRGO) is down $2.28 (-1.9%) to $120.03 on heavy volume. Thus far, 2.0 million shares of Perrigo Company exchanged hands as compared to its average daily volume of 1.0 million shares. The stock has ranged in price between $119.28-$120.98 after having opened the day at $120.00 as compared to the previous trading day's close of $122.31.

Perrigo Company, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API) worldwide. Perrigo Company has a market cap of $11.9 billion and is part of the health care sector. Shares are up 17.6% year to date as of the close of trading on Thursday. Currently there are 11 analysts that rate Perrigo Company a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Perrigo Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Perrigo Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Bristol-Myers Squibb Company ( BMY) is down $0.36 (-0.9%) to $41.62 on average volume. Thus far, 5.0 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 9.4 million shares. The stock has ranged in price between $41.26-$42.14 after having opened the day at $41.85 as compared to the previous trading day's close of $41.98.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $70.7 billion and is part of the health care sector. Shares are up 28.8% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Pfizer ( PFE) is down $0.33 (-1.1%) to $28.47 on light volume. Thus far, 14.0 million shares of Pfizer exchanged hands as compared to its average daily volume of 60.1 million shares. The stock has ranged in price between $28.47-$28.68 after having opened the day at $28.65 as compared to the previous trading day's close of $28.80.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $192.2 billion and is part of the health care sector. Shares are up 14.8% year to date as of the close of trading on Thursday. Currently there are 10 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Pfizer Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings

Veteran Foreign Affairs Expert Ian Bremmer Reveals How to Price Political Risk

Veteran Foreign Affairs Expert Ian Bremmer Reveals How to Price Political Risk